21.82MMarket Cap-1176P/E (TTM)
0.9998High0.9500Low141.48KVolume0.9900Open0.9800Pre Close137.05KTurnover0.68%Turnover RatioLossP/E (Static)22.90MShares2.400052wk High3.65P/B19.70MFloat Cap0.734052wk Low--Dividend TTM20.67MShs Float13.7500Historical High--Div YieldTTM5.08%Amplitude0.2479Historical Low0.9680Avg Price1Lot Size
Femasys Stock Forum
Femasys Inc., a leading biomedical company, has filed an amended Form 8-K/A with the SEC to correct previously reported dates. The amendment, dated November 12, 2024, rectifies the 'Date of Report' and related references from August 12, 2024, to the correct date of November 12, 2024. Alongside this administrative correction, Femasys announced its financial results for the third quarter ended September 30, 2024.
The company reported a significant increase in sales, primari...
1 min ago
Femasys Announces Issued U.S. Patent Covering Fembloc® Device for Female Permanent Birth Control
Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control
Femasys Inc. (NASDAQ: FEMY) announces the issuance of U.S. Patent No. 12,12796 by the USPTO for its FemBloc® permanent birth control device. The patent, expiring no earlier than 2039, strengthens the company's intellectual property position for its leading therapeutic product candidate. This adds to Femasys' portfolio of over 180 patents globally, protecting their suite of prod...
Femasys Announces Partnership With Boston IVF, Prominent Network of Fertility Centers, to Offer Femaseed
Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments
ATLANTA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the Company has received its second order from its strategic distribut...
·3 mins ago
Femasys Secures Strategic Distribution Partnerships for Commercialization of Femaseed® for Over $1.3M in Spanish Market
Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market
Share on Reddit
Share on Facebook
09/11/2024 - 05:30 AM
Company taps Comercial Medico Quirurigca, SA and Durgalab as first EU distributors for its CE-marked women’s reproductive healthcare products
ATLANTA, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of wome...
Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check
ATLANTA, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, today announced it has received 510(k) clearance from the United States Food and Drug Ad...
No comment yet